This is a remote position for those based in Ireland & the United Kingdom & NI or on the East Coast of the US. We have lab operations in New York and Salt Lake City (US) and a tech-focused hub in Kilkenny (Ireland).
If you prefer working remotely, are passionate about Azure and would like to be one of the first technical hires in a publicly listed company providing AI solutions to drive improvements in kidney health for millions of patients worldwide, then keep reading!
We’re looking for a DevOps Engineer to help build, manage, and optimise RenalytixAI’s cloud infrastructure whilst working with the development team to ensure high-quality and thorough code deployments.
RenalytixAI was established in 2018 with the vision of providing advanced technology solutions to drive improvements in kidney health for millions of patients worldwide. KidneyIntelX, our first-in-class diagnostic platform, employs a proprietary artificial intelligence-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics, and extensive personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score.
This patient risk score enables the prediction of adverse kidney outcomes in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at the highest risk.
As a DevOps Engineer, you will build infrastructure to support our cloud-based applications on Azure, create deployment architect and continuous delivery pipelines, design high-availability approaches, and implement monitoring architecture (dashboards, alerts, escalations).
A large part of your role will be to help evolve our Kubernetes environment to maximise the availability and performance of our applications and services. As there is ongoing development as both our KidneyIntelX platform and our Provider app, you will work closely with the various development teams to build CI/CD pipelines and develop a standard operating procedure around code deployments; we operate in a highly regulated industry so it is imperative that code deployments are well documented
Salary: £60,000 - £90,000
RenalytixAI is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs. Our goal is to lower healthcare costs and improve patient quality of life by transforming the paradigm for kidney disease risk assessment and clinical management through our KidneyIntelX platform.
KidneyIntelX, our first-in-class diagnostics platform, employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score.
This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk. We plan are deploying KidneyIntelX to patient populations with DKD on a regional basis through partnerships with healthcare systems and insurance payors that provide coverage to those healthcare systems’ patients.
CKD affects approximately 37 million individuals in the United States, significantly impacting their quality of life and resulting in Medicare spending of at least $114 billion per year. In response to this substantial kidney disease burden, a U.S. Presidential Executive Order on Advancing American Kidney Health was issued in July 2019 to support comprehensive change in kidney disease care.
KidneyIntelX is a powerful prognostic tool that can help slow the progression of kidney disease and potentially prevent the occurrence of progressive kidney function decline such as kidney failure and the need for long-term dialysis or kidney transplant. We are continuing to publish a body of evidence through clinical validation studies and patient data generation to demonstrate that accurate and early identification of high-risk patients, coupled with guidelines-driven clinical recommendation designed to maximize patient treatment and compliance, can have a measurable positive impact on patient quality of life.
Our executive team has an average of 25 years’ experience in different professional disciplines including bioinformatics, digital health, data security, market access, commercial operations, medical affairs, insurance reimbursement, FDA regulation and ISO quality management systems, population health, clinical medicine and health economics. We believe the integration of such diverse experience is essential to understanding the complex dynamics of deploying a new technology into the highly regulated world of patient clinical care, and we have assembled our team specifically with this multidisciplinary approach in mind.
The company is listed on the London Stock Exchange (LSE.RENX) and the Nasdaq, we have laboratory operations in New York City and Salt Lake City with offices in Cardiff UK and Kilkenny Ireland.